The highly effective CFTR modulator therapy (HEMT) ETI is available for patients with at least one F508del allele (approximately 85% of the CF population), and in some countries, for patients with this and one other mutation in the CF gene that is responsive to ETI, resulting in lower need for LTX in those patients in multiple countries.19, 22 It is important to note that ETI; however, is not accessible in several countries.23 Here, CFTR is linked to cystic fibrosis.